



Supplementary Material

Supplementary Figure S1. Forest plot of pooled odds ratios for overall response rate (ORR) in patients who received PD-(L)1 inhibitors plus chemotherapy *vs.* chemotherapy alone. **Treat.**, events in treatment arm/total; **Ctr.**, events in control arm/total; **CI**, confidence interval; **OR**, odds ratio.




Supplementary Figure S2. Forest plot of pooled hazard ratios for (A) progression-free survival (PFS) and (B) overall survival in patients with non-squamous or squamous NSCLC who received PD-(L)1 inhibitors plus chemotherapy *vs.* chemotherapy alone. **HR**, hazard ratio; **CI**, confidence interval. **IM.**, IMpower; **KN.**, KEYNOTE; **CM.** CheckMate

A



B



Supplementary Table S1. Treatments previously administered for nonmetastatic disease (data not available for atezolizumab studies)

Studies	Thoracic radiation		Neoadjuvant therapy		Adjuvant therapy	
	Control <i>n</i> (%)	Treatment <i>n</i> (%)	Control <i>n</i> (%)	Treatment <i>n</i> (%)	Control <i>n</i> (%)	Treatment <i>n</i> (%)
KEYNOTE-189 [30, 31]	20 (9.70)	28 (6.8)	6 (2.90)	5 (1.20)	14 (6.80)	25 (6.10)
KEYNOTE-407 [24]	22 (7.80)	17 (6.10)	8 (2.80)	5 (1.80)	NA	NA

NA, not applicable

Supplementary Table S2. Mutation status of IMpower150 [25, 26] study patients.

Mutation status	Negative		Positive	
	Control arm <i>n</i> (%)	Experimental arm <i>n</i> (%)	Control arm <i>n</i> (%)	Experimental arm <i>n</i> (%)
EGFR	345 (86.30)	352 (88)	45 (11.30)	34 (8.80)
EML4-ALK	375 (93.80)	383 (95.80)	21 (5.20)	13 (3.20)
KRAS	77 (19.20)	59 (14.80)	38 (9.50)	47 (11.80)

Supplementary Table S3. Characteristics of the patient population of the studies included in the meta-analysis.

Study	Experimental arm	Total <i>n</i>	Men <i>n</i> (%)	Median age (range)	Current or former smokers <i>n</i> (%)	PD-L1 high/low- intermediate/negative (%)	ECOG-PS 0/1/2 (%)	Liver metastasis <i>n</i> (%)	Bone metastasis <i>n</i> (%)	Brain metastasis <i>n</i> (%)
IMpower 130 [27]	Atezolizumab + [carbo + nab- paclitaxel]	451	266 (59)	64 [18- 86]	403 (89)	20/28/52	42/58/0	69 (15)	126 (28)	NA
IMpower 150 [25, 26]	Atezolizumab + [carbo + paclitaxel + bevacizumab]	356	240 (60)	63 [31- 89]	318 (79.50)	19/87/48	40.10/59.90/0	53 (13.20)	NA	NA
KEYNOTE- 189 [30, 31]	Pembrolizumab + [carbo or cisplatin + pemetrexed]	410	254 (62)	65 [34- 84]	362 (88.30)	32.2/31/31	45.40/53.90/0.2	66 (16)	NA	73 (17.80)
IMpower 132 [22]	Atezolizumab + [carbo or cisplatin + pemetrexed]	292	192 (65.8)	64 [31- 85]	255 (87.30)	14.20/35.8/50	43.20/53.8/0	37 (12.70)	NA	NA
IMpower 131 [32]	Atezolizumab + [carbo + nab- paclitaxel]	343	279 (81)	65 [23- 83]	311 (91)	15/38/47	34/66/0	70 (20)	NA	NA
KEYNOTE- 407 [24]	Pembrolizumab + [carbo + paclitaxel or nab-paclitaxel]	278	220 (79.1)	65 [29- 87]	256 (92.10)	26.30/37.10/34.20	26.30/76.70	NA	NA	20 (7.20)
CheckMate- 227 [23]	Nivolumab and ipilimumab + Platinum-doublet chemotherapy* (<i>n</i> = 377)	377	264 (70)	63 [27- 84]	317 (84)	24/34/40	35/64/1	87 (23)	109 (29)	NA
**Carboplatin or cisplatin plus gemcitabine or pemetrexed or paclitaxel PD-L1, programmed cell death-ligand 1; ECOG-PS, Eastern Cooperative Oncology Group performance status; Carbo, carboplatin; NA, not applicable										

